Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.042 USD | +2.97% | +3.63% | +17.15% |
Mar. 21 | Xenetic Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Mar. 18 | CLS Therapeutics Discloses its Views on Xenetic Biosciences | CI |
Sales 2024 * | 2.13M 2.67M | Sales 2025 * | 1.42M 1.78M | Capitalization | 4.84M 6.06M |
---|---|---|---|---|---|
Net income 2024 * | -4M -5.01M | Net income 2025 * | -8M -10.02M | EV / Sales 2024 * | 2.27 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 3.41 x |
P/E ratio 2024 * |
-1.14
x | P/E ratio 2025 * |
-4.79
x | Employees | 4 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 80.81% |
1 day | +2.97% | ||
1 week | +3.63% | ||
Current month | -6.01% | ||
1 month | -14.37% | ||
3 months | +4.71% | ||
6 months | +37.01% | ||
Current year | +17.15% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 58 | 16-07-10 | |
James F. Parslow
DFI | Director of Finance/CFO | 59 | 17-04-02 |
Curtis Lockshin
CTO | Chief Tech/Sci/R&D Officer | 64 | 14-02-28 |
Members of the board | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 58 | 16-07-10 | |
Moshe Mizrahy
BRD | Director/Board Member | 71 | - |
Adam Logal
CHM | Chairman | 46 | 17-08-13 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-08 | 3.925 | +1.95% | 1,695 |
24-05-07 | 3.85 | -2.78% | 3,398 |
24-05-06 | 3.96 | -7.26% | 10,893 |
24-05-03 | 4.27 | +9.49% | 5,746 |
24-05-02 | 3.9 | -5.68% | 1,052 |
Delayed Quote Nasdaq, May 09, 2024 at 04:30 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+17.15% | 6.05M | |
+2.97% | 108B | |
+10.21% | 105B | |
+1.57% | 23.46B | |
-12.77% | 21.72B | |
-7.05% | 18.64B | |
-37.64% | 17.45B | |
-6.50% | 17.19B | |
+6.00% | 13.99B | |
+37.20% | 12.53B |
- Stock Market
- Equities
- XBIO Stock